---
schema_version: "secwatch.filing_event.v1"
accession: "0001804220-23-000029"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T01:24:55.070945+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Regeneron Q3 revenue $3.36B (+15%); GAAP EPS $8.89, non-GAAP EPS $11.59; EYLEA HD launch begins

## Summary
- Revenue $3.363B (+15% YoY); GAAP EPS $8.89, non-GAAP EPS $11.59.
- EYLEA HD launched post-FDA approval, generated $43M U.S. net sales in Q3.
- Dupixent global net sales (Sanofi) $3.10B (+33% YoY); Libtayo global net sales $232M (+62%).
- FDA accepted priority reviews for odronextamab in FL/DLBCL and Dupixent in pediatric EoE; CRL for Dupixent in CSU.
- CFO Robert Landry to retire Feb 2024; Christopher Fenimore to succeed.

## SEC filing metadata
- accession: 0001804220-23-000029
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/0001804220-23-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/regn-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001804220-23-000029
- JSON: https://secwatch.observer/filing/0001804220-23-000029.json
- Plain text: https://secwatch.observer/filing/0001804220-23-000029.txt

## Key facts
- Earnings Releases
  REGENERON PHARMACEUTICALS, INC. reported the quarter ended September 30, 2023 results: revenue $3,363, net income $1,008, EPS $8.89.
  - Period: the quarter ended September 30, 2023
  - Revenue: $3,363
  - Net income: $1,008
  - EPS: $8.89
  - Result: reported results
  source text: to our portfolio through the recent acquisition of Decibel Therapeutics." Financial Highlights ($ in millions, except per share data) Q3 2023 Q3 2022 % Change Total revenues $ 3,363 $ 2,936 15 % GAAP net income $ 1,008 $ 1,316 (23 %) GAAP net income per share - diluted $ 8.89 $ 11.66 (24 %) Non-GAAP net income (a) $ 1,329 $ 1,270 5 % Non-GAAP net income per
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000180422023000029/0001804220-23-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.